Assembly biosciences, inc. (ASMB)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Cash flows from operating activities
Net loss

-26,655

-

-24,995

-18,503

-27,052

-

-21,535

-26,806

-16,249

-

-12,272

-13,598

-13,930

-11,546

-11,574

-10,152

-10,988

-7,748

-6,617

-6,942

-7,144

-6,229

-11,020

-2,469

-4,069

-6,047

-4,881

-4,751

-3,723

-3,791

-5,355

-7,470

-8,173

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

115

117

117

125

135

170

161

144

168

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based payments to consultants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

16

13

33

66

225

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

41

50

31

24

18

18

18

17

17

16

13

7

1

1

1

1

1

1

1

1

1

1

0

Stock-based compensation

4,924

6,509

5,404

2,068

6,577

6,807

6,006

11,589

4,083

2,767

2,597

2,011

1,224

990

1,055

1,518

1,459

1,521

1,149

2,620

2,585

2,635

7,434

312

254

261

472

711

268

589

701

826

714

Net accretion and amortization of investments in marketable securities

135

232

362

549

592

461

-232

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash rent expense

1,151

1,110

1,136

1,117

1,091

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Realized loss from marketable securities

-

-

-

-

-

-

-

-

-

-

-

-340

-137

-521

-273

-142

-201

-28

1

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax benefit

0

-790

8

-11

-7

1,140

-6

-34

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of fixed assets

0

0

0

0

-102

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

0

0

0

4

1

0

150

-127

-23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of deferred financing costs and debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Non-cash research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Expenses paid on behalf of the Company satisfied through the issuance of notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Changes in operating assets and liabilities:
Accounts receivable from collaboration

-319

430

41

-84

557

-160

464

-138

-10

872

286

1,113

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-795

-78

-1,305

2,510

2,558

-1,351

611

928

906

-54

-27

-320

687

1

52

-209

61

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-23

13

-22

32

-1,687

2,397

611

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

100

321

158

-

-324

172

195

-71

-42

-46

164

-51

-45

-101

196

Accounts payable

373

-978

-705

987

-1,266

706

448

166

249

1,253

182

-1,259

-420

-1,470

1,424

87

962

-100

160

113

283

-0

-1,288

-13

-1,179

-

-

-

-

-

-

-

-

Accrued clinical expenses

-193

-

-

-

3,077

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other accrued expenses

-3,808

-

-

-

-2,679

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-

-

-

-

-

-

1,437

432

-1,491

-

46

2,291

-739

1,108

1,013

1,387

-796

828

251

157

731

5

-6

21

3

-

-

-

-

-

-

-

-

Deferred revenue

-1,007

-

-

-

-859

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-894

-1,301

-

-1,259

-1,245

49,315

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-1,120

-

-

-

-1,037

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-86

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Security deposits

-

-

-

-

-

-

-

-

-

-

-98

-85

13

-

-21

20

-7

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-16

-

-

-

0

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-267

608

-768

64

-710

-461

1,339

Net cash used in operating activities

-25,218

-20,528

-18,595

-21,005

-23,939

-16,727

-16,684

-16,047

-15,500

-9,770

-10,957

-12,357

34,944

-11,039

-7,864

-6,767

-9,210

-5,455

-5,186

-4,382

-3,673

-3,592

-3,875

-2,320

-5,185

-5,392

-4,655

-3,378

-4,370

-3,070

-5,283

-6,935

-6,089

Cash flows from investing activities
Purchases of property and equipment

65

15

0

51

1,488

211

37

53

39

361

503

0

0

111

32

0

2

10

0

17

30

129

17

0

2

1

0

5

0

-

-

-

-

Purchases of marketable securities

44,242

-

-

-

49,030

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

55,000

-

-

-

61,453

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of marketable securities

10,000

-

-

-

500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

19,135

13,032

-

7,431

32,591

0

-0

-0

0

7,951

6,112

14,887

48,780

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

-

-

-

-

-

-

-

20,650

11,971

-

6,423

13,475

6,658

15,778

11,350

6,714

10,451

2,283

2,699

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of marketable securities

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

20,693

-95,022

7,819

25,450

11,435

-62,159

-73,600

1,462

-1,100

-1,673

-1,510

-19,116

6,658

15,667

11,317

6,714

2,497

-3,838

-12,187

-48,798

-30

-211

491

0

-2

-1

0

-5

0

-

-

-

-

Cash flows from financing activities
Proceeds from the exercise of stock options

-

-

-

-

-

-

-

-

-

-

262

108

640

153

0

0

0

0

257

129

167

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options

119

-

-

-

140

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from the issuance of common stock through equity plans

-

-

-

-

-

-

419

1,850

1,494

-

-

-

-

-

-

-

-

0

0

10,514

70,499

14,962

0

0

1,763

232

3,388

0

20,754

0

0

4,166

0

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Proceeds from notes payable to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Payment for deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-57

57

Repayment of notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Repayment of notes payable - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Proceeds from the exercise of warrants and options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

491

238

Net cash provided by financing activities

119

137,415

1,385

706

140

605

155,844

1,850

1,494

66,229

262

108

640

153

0

0

0

0

257

10,644

70,667

14,962

0

0

1,763

232

3,388

0

20,754

0

0

4,716

180

Net decrease in cash and cash equivalents

-4,406

-

-

-

-12,364

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-15,106

-

-12,205

-31,365

42,242

4,780

3,452

-53

-6,712

-9,293

-17,116

-42,535

66,962

11,158

-3,383

-2,320

-3,424

-5,161

-1,267

-3,383

16,384

-3,070

-5,283

-2,222

-5,908

Change in unrealized (loss) gain on marketable securities available-for-sale

-

-

-

-

-

-

-

-

-

-

-

-

76

-

2

-89

72

-433

-253

-134

0

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

Supplemental non-cash investing and financing activities
Operating lease liabilities arising from obtaining ROU assets

362

-

-

-

13,933

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued offering cost related to the issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-60

-

-

-

0

-

-

-

-

-

-

-

-

Warrants issued to placement agent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Warrants issued to investors in connection with convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Notes and accrued interest converted to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Supplemental disclosure - cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0